Skip to content

Red flags and safety concerns

TL;DR — The primary red flags are leukocoria, new strabismus and any suspected intraocular mass in a young child; delay permits extraocular extension. Safety hazards include transocular biopsy, injection through tumour or detached retina, delaying enucleation for an unsalvageable eye, and treating heritable and non-heritable survivors as one late-risk group. MRI avoids ionising radiation for staging; repeated anaesthesia and low-yield surveillance also carry burdens. This page describes research-supported safety boundaries, not individual medical advice.

Decision-relevant evidence

  • Advanced cT4 disease independently carried mortality HR 8.98 (95% CI 4.44–18.18) versus cT1 in the global cohort, and low-income residence HR 16.67 (4.76–50.00) (PMID 35839812). Stage at presentation, not treatment sophistication, is the largest modifiable determinant of death.

  • Mean symptom-to-treatment delay of 4.2 months correlated with advanced stage in a prospective 1,120-child study; first consultation with a non-specialist was significantly associated with longer lag (P = 0.001), and 25.2% already had extraocular or metastatic disease at diagnosis (Das 2025, PMID 40719713).

  • The consequence of not treating is documented, not hypothetical: among 44 children who abandoned treatment at diagnosis, median intervals were 13.7 months from intraocular diagnosis to orbital disease, 2.6 months to metastasis and 2.0 months to death, with 36% dead by 12 months and 100% by 48 months (Zhao 2021, PMID 34359552).

  • A preceding minor trauma is a documented route to misdiagnosis. Of 793 consecutive retinoblastoma patients, 10 (1.3%) had a trauma history before diagnosis; two of those 10 had already undergone vitrectomy on an eye with an unsuspected tumour, only five of ten were initially recognised as retinoblastoma or an intraocular mass before referral, eight of ten were cT2b or higher and enucleated, and two died of intracranial metastasis over mean 25.9 months (Chen 2019, PMID 31827335). Intraocular surgery on an unrecognised retinoblastoma is the specific harm to avoid.

  • Transocular biopsy and vitrectomy are avoided for the same reason, which is why aqueous-humour cell-free DNA has been developed as the substitute route to molecular information (Harbour 2017, PMID 29049432; Sanchez 2025, PMID 40213298).

  • Diagnostic imaging carries its own safety trade-off: high-resolution MRI is the modality of choice and CT is no longer indicated despite characteristic calcification, because a large fraction of these children carry a germline RB1 variant that makes ionising radiation a lifetime risk rather than a procedural one (Schweiger 2022, PMID 35969246).

  • That radiation risk is quantified: sarcoma risk in hereditary survivors was evident above 5 Gy and rose to 10.7-fold at ≥60 Gy, and all 114 sarcomas in a 1,604-patient cohort occurred in hereditary patients (Wong 1997, PMID 9333268). In-field head-and-neck bone sarcoma reached SIR 2,213 (95% CI 1,671–2,873) in irradiated hereditary survivors (Kleinerman 2019, PMID 31622129).

  • Intravitreal injection is performed with an anti-reflux technique and needle-track sterilisation precisely because the procedure crosses the tumour-containing compartment; the founding safety series reported no clinically detected extraocular spread and no tumour at the histologically examined entry sites of five enucleated eyes over 135 injections, with transient localised vitreous haemorrhage in 3 of 135 (Munier 2012, PMID 22368262). A zero-event series of this size cannot exclude a low seeding rate.

  • Intravitreal chemotherapy also carries measurable ocular toxicity at standard dose: 59% of 27 eyes developed a side effect, including retinal toxicity in 48% and cataract in 30% (Yousef 2021, PMID 34322023), and a phase I intravitreal carboplatin trial closed early after one of four patients lost vision with an extinguished electroretinogram 72 hours after the second injection (King 2023, PMID 36372348).

  • Arterial delivery has route-specific vascular harms: ophthalmic-artery stenosis in 18% and occlusion in 3% in the randomized trial (Wen 2023, PMID 37536351), and severe physiological reactions requiring adrenaline in six patients during catheterisation in one refractory-disease cohort (Reddy 2017, PMID 28432112). Multi-institutional experience shows the procedure itself is not reliably deliverable outside expert centres: only 67% feasibility success in a nine-institution cooperative study (Chintagumpala 2024, PMID 37817345).

  • Prolonged eye-salvage attempts in advanced eyes are a safety issue, not only an efficacy one: delay from diagnosis to enucleation beyond 3.5 months (group D) or 2 months (group E) reduced disease-specific survival, and four or more pre-enucleation cycles in group E worsened survival compared with primary enucleation (Zhao 2020, PMID 32387053).

  • Following all cystic pineal glands required 494 scans per pineal tumour detected in a 607-patient cohort, against 22 when follow-up was restricted to suspicious glands; screening sensitivity for pineal trilateral disease was 25% (de Bloeme 2024, PMID 38992673). Repeated anaesthesia and low-yield imaging are themselves burdens to be weighed.

  • Neglected disease still presents, and its complications are severe: orbital retinoblastoma complicated by orbital myiasis after treatment non-compliance required exenteration and adjuvant radiotherapy in a 4-year-old with a white reflex present since birth (Panda 2025, PMID 41645972).

  • Congenital brain anomalies with 13q involvement warrant ocular vigilance: bilateral retinoblastoma has been reported in Dandy-Walker syndrome, both entities having been linked to chromosome 13q abnormalities (Lomi 2025, PMID 40926918). This is a single case report and establishes awareness, not an association.

Clinical and research frame

Domain Operational meaning Evidence boundary
Leukocoria/new squint Urgent specialist eye examination Delay-stage relationship
Suspected intraocular tumour Do not perform routine needle/incisional biopsy Preserve ocular containment
Injection therapy Expert safety protocol and tumour-free site Prevent extraocular tract seeding
Painful blind advanced eye Do not let salvage ambition delay life-saving control Life before globe
Heritable survivor Avoid unnecessary ionising radiation Genetic plus treatment-related SMN risk
Non-heritable survivor Do not assign heritable SMN estimates Risk groups remain distinct

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
40719713 2025 Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Topic-resolved source (Das 2025, PMID 40719713)
22368262 2012 Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Topic-resolved source (Munier 2012, PMID 22368262)
9333268 1997 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. Topic-resolved source (Wong 1997, PMID 9333268)
38992673 2024 Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. Topic-resolved source (de 2024, PMID 38992673)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
28695165 2017 Neonatal Retinoblastoma. Topic-resolved source (Kivelä 2017, PMID 28695165)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
21849363 2011 MRI of retinoblastoma. Topic-resolved source (Razek 2011, PMID 21849363)
29049432 2017 Liquid Biopsy in Retinoblastoma. Topic-resolved source (Harbour 2017, PMID 29049432)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
36408154 2022 Retinoblastoma: Review and new insights. Topic-resolved source (Cruz-Gálvez 2022, PMID 36408154)
40731848 2025 Update on Retinoblastoma Therapies. Topic-resolved source (Martínez 2025, PMID 40731848)
32206913 2020 [Retinoblastoma]. Topic-resolved source (Bornfeld 2020, PMID 32206913)
37602177 2023 Adult-onset retinoblastoma: An uncommon and challenging diagnosis. Topic-resolved source (Verma 2023, PMID 37602177)
25473349 2014 Retinoblastoma: An overview. Topic-resolved source (Pandey 2014, PMID 25473349)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
25940424 2015 Retinoblastoma: diagnosis and management--the UK perspective. Topic-resolved source (Jenkinson 2015, PMID 25940424)
40213298 2025 Retinoblastoma: Aqueous humor liquid biopsy. Topic-resolved source (Sanchez 2025, PMID 40213298)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
26969537 2016 Retinoblastoma: An update. Topic-resolved source (Delhiwala 2016, PMID 26969537)
38263682 2024 Global retinoblastoma studies: A review. Topic-resolved source (Vempuluru 2024, PMID 38263682)
40471757 2025 Managing retinoblastoma in 2025. Topic-resolved source (Ramos-Dávila 2025, PMID 40471757)
41645972 2025 Orbital myiasis in neglected orbital retinoblastoma. Topic-resolved source (Panda 2025, PMID 41645972)
40926918 2025 Retinoblastoma in Dandy-Walker Syndrome. Topic-resolved source (Lomi 2025, PMID 40926918)
38609685 2024 Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Meel 2024, PMID 38609685)
30350021 2019 Expression profiles and prognostic value of miRNAs in retinoblastoma. Topic-resolved source (Delsin 2019, PMID 30350021)
41280625 2025 Retinoblastoma management in China: clinical challenges. Topic-resolved source (Wang 2025, PMID 41280625)
34359552 2021 Natural History of Untreated Retinoblastoma. Topic-resolved source (Zhao 2021, PMID 34359552)
31827335 2019 Head and Eye Trauma Before Retinoblastoma Diagnosis. Topic-resolved source (Chen 2019, PMID 31827335)
29337595 2017 Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Topic-resolved source (Pant 2017, PMID 29337595)
18762512 2008 Retinoblastoma: one world, one vision. Topic-resolved source (Rodriguez-Galindo 2008, PMID 18762512)
36938376 2022 Clinicopathological Presentation of Retinoblastoma in Ethiopia. Topic-resolved source (Sherief 2022, PMID 36938376)
35969246 2022 [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Added by audit 2026-09-01 (Schweiger 2022, PMID 35969246)
31622129 2019 Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. Added by audit 2026-09-01 (Kleinerman 2019, PMID 31622129)
34322023 2021 Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma. Added by audit 2026-09-01 (Yousef 2021, PMID 34322023)
36372348 2023 Intravitreal Carboplatin as Salvage Treatment for Progressive Vitreous Disease in Retinoblastoma: A Phase I Clinical Trial. Added by audit 2026-09-01 (King 2023, PMID 36372348)
37536351 2023 Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Added by audit 2026-09-01 (Wen 2023, PMID 37536351)
28432112 2017 Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Added by audit 2026-09-01 (Reddy 2017, PMID 28432112)
37817345 2024 A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Added by audit 2026-09-01 (Chintagumpala 2024, PMID 37817345)
32387053 2020 Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma. Added by audit 2026-09-01 (Zhao 2020, PMID 32387053)

Source chronology

Era marker PMID What the record contributes
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
1997 9333268 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. (Wong 1997, PMID 9333268)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2008 18762512 Retinoblastoma: one world, one vision. (Rodriguez-Galindo 2008, PMID 18762512)
2011 21849363 MRI of retinoblastoma. (Razek 2011, PMID 21849363)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22368262 Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. (Munier 2012, PMID 22368262)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2014 25473349 Retinoblastoma: An overview. (Pandey 2014, PMID 25473349)
2015 25940424 Retinoblastoma: diagnosis and management--the UK perspective. (Jenkinson 2015, PMID 25940424)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 26023180 Retinoblastoma. (Ortiz 2016, PMID 26023180)
2016 26969537 Retinoblastoma: An update. (Delhiwala 2016, PMID 26969537)
2017 28620731 Retinoblastoma. (Rao 2017, PMID 28620731)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • What referral threshold minimizes false reassurance without overwhelming specialist services? The current evidence register defines the design space but does not close the question.

  • How should procedural safety events be reported across centers? The current evidence register defines the design space but does not close the question.

  • Can surveillance be reduced without missing treatable trilateral disease? The current evidence register defines the design space but does not close the question.

References

  1. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  2. Das S, et al. Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Indian journal of ophthalmology. 2025;73:1124-1131. PMID 40719713
  3. Munier FL, et al. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. The British journal of ophthalmology. 2012;96:1084-7. PMID 22368262
  4. Wong FL, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262-7. PMID 9333268
  5. de Bloeme CM, et al. Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. American journal of ophthalmology. 2024;268:199-211. PMID 38992673
  6. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  7. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  8. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  9. Kivelä TT, et al. Neonatal Retinoblastoma. Asia-Pacific journal of oncology nursing. 2017;4:197-204. PMID 28695165
  10. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  11. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  12. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  13. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  14. Razek AA, et al. MRI of retinoblastoma. The British journal of radiology. 2011;84:775-84. PMID 21849363
  15. Harbour JW. Liquid Biopsy in Retinoblastoma. JAMA ophthalmology. 2017;135:1231. PMID 29049432
  16. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  17. Cruz-Gálvez CC, et al. Retinoblastoma: Review and new insights. Frontiers in oncology. 2022;12:963780. PMID 36408154
  18. Martínez Arce CA, et al. Update on Retinoblastoma Therapies. Medicina (Kaunas, Lithuania). 2025;61. PMID 40731848
  19. Bornfeld N, et al. [Retinoblastoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2020;117:389-402. PMID 32206913
  20. Verma R, et al. Adult-onset retinoblastoma: An uncommon and challenging diagnosis. Oman journal of ophthalmology. 2023;16:382-384. PMID 37602177
  21. Pandey AN. Retinoblastoma: An overview. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2014;28:310-5. PMID 25473349
  22. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  23. Jenkinson H. Retinoblastoma: diagnosis and management--the UK perspective. Archives of disease in childhood. 2015;100:1070-5. PMID 25940424
  24. Sanchez GM, et al. Retinoblastoma: Aqueous humor liquid biopsy. Taiwan journal of ophthalmology. 2025;15:55-61. PMID 40213298
  25. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  26. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  27. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  28. Delhiwala KS, et al. Retinoblastoma: An update. Seminars in diagnostic pathology. 2016;33:133-40. PMID 26969537
  29. Vempuluru VS, et al. Global retinoblastoma studies: A review. Clinical & experimental ophthalmology. 2024;52:334-354. PMID 38263682
  30. Ramos-Dávila EM, et al. Managing retinoblastoma in 2025. Current opinion in ophthalmology. 2025;36:414-426. PMID 40471757
  31. Panda BB, et al. Orbital myiasis in neglected orbital retinoblastoma. The National medical journal of India. 2025;38:353-354. PMID 41645972
  32. Lomi N, et al. Retinoblastoma in Dandy-Walker Syndrome. Cureus. 2025;17:e89663. PMID 40926918
  33. Meel R, et al. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1166-1176. PMID 38609685
  34. Delsin LEA, et al. Expression profiles and prognostic value of miRNAs in retinoblastoma. Journal of cancer research and clinical oncology. 2019;145:1-10. PMID 30350021
  35. Wang N, et al. Retinoblastoma management in China: clinical challenges. International journal of ophthalmology. 2025;18:2380-2384. PMID 41280625
  36. Zhao J, et al. Natural History of Untreated Retinoblastoma. Cancers. 2021;13. PMID 34359552
  37. Chen R, et al. Head and Eye Trauma Before Retinoblastoma Diagnosis. Cancer management and research. 2019;11:10269-10274. PMID 31827335
  38. Pant G, et al. Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Pediatric hematology and oncology. 2017;34:419-424. PMID 29337595
  39. Rodriguez-Galindo C, et al. Retinoblastoma: one world, one vision. Pediatrics. 2008;122:e763-70. PMID 18762512
  40. Sherief ST, et al. Clinicopathological Presentation of Retinoblastoma in Ethiopia. Ocular oncology and pathology. 2022;8:168-174. PMID 36938376
  41. Schweiger B, et al. [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Radiologie (Heidelberg, Germany). 2022;62:1067-1074. PMID 35969246
  42. Kleinerman RA, et al. Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3436-3445. PMID 31622129
  43. Yousef YA, et al. Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma. Frontiers in pharmacology. 2021;12:696787. PMID 34322023
  44. King BA, et al. Intravitreal Carboplatin as Salvage Treatment for Progressive Vitreous Disease in Retinoblastoma: A Phase I Clinical Trial. Ophthalmology. Retina. 2023;7:354-359. PMID 36372348
  45. Wen X, et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. The Lancet. Child & adolescent health. 2023;7:613-620. PMID 37536351
  46. Reddy MA, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. The British journal of ophthalmology. 2017;101:1704-1708. PMID 28432112
  47. Chintagumpala M, et al. A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Pediatric blood & cancer. 2024;71:e30718. PMID 37817345
  48. Zhao J, et al. Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma. Ophthalmology. Retina. 2020;4:630-639. PMID 32387053